Michael Kolodziej, MD: Biosimilars in Alternative Payment Models

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc, addresses the role that biosimilars will have in alternative payment models in oncology.
October 23, 2019


Without a doubt, they'll be integrated. And I think it's funny; I gave a talk yesterday to the New York State Society of Oncology about biosimilars, and really there were 2 messages. One is, if we look back on the history of oncology, and how generics changed things, people embraced generics, and honestly, they mitigated the cost magnificently.

Now, I'm not an idiot. I understand biosimilars are different. However, the regulatory process that the FDA is put in place for biosimilars is extremely rigorous, and I think most oncologists are going to be comfortable prescribing them, and as time goes on, they’ll be more and more comfortable prescribing them.

If we look at Europe, there have been no ill effects of biosimilars and they’re 10 years ahead of us. So I think that, if you're in an alternative payment model, that is easy for you to do, it doesn't force you to confront utilization, physician practice behavior—it's easy.

Now, there's a flip side to this. Even if you don't want to do it, the payers are going to make you do it. And each payer may wind up with a different biosimilar of choice. But payers, even if they're not in a value-based care model, are going to force you to do it. There’s just no question about it.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.